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prostate cancer) (C60-63), 10.7% had malignant neoplasms of digestive organs (C15-
26) and 8,4% showed malignant neoplasms of ill-defined, secondary and unspecified 
sites (C76-80). The outpatient diagnosis rate for CLL was 94.9%, inpatient rate 0.6% 
and in-and outpatient rate 4.6%. Overall, 266 of 1,405 pts (18.9%) (175 men [65.8%], 91 
women [34.2%]) received chemotherapy in 2012 (ATC Code L01* 74.1%, PZN 9999092 
23.0%, OPS 854* 2.9%). Most patients received outpatient treatment (94.0%), with 5.3% 
of patients received both out- and inpatient treatment and 0.7% inpatient treat-
ment. The most commonly used treatments were rituximab (26.7%), bendamustine 
(20.2%), chlorambucil (11.1%), cyclophosphamide (7.7%), fludarabine (6.2%) and other 
treatments (28.1%). ConClusions: The majority of patients being diagnosed with 
CLL did not require treatment within a time period of a year. Approximately 1/3 
of patients had a second malignancy, predominantly skin cancer. Treatment was 
primarily composed of chemotherapy or chemoimmunotherapy.
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objeCtives: To estimate the annual number of patients in France with Acute 
Myeloid Leukemia (AML) and MyeloDysplasic Syndrom (MDS) and treated with 
intensive chemotherapy susceptible to induce neutropenia. Methods: French hos-
pital databases named PMSI record medical information about all the hospitaliza-
tions performed annually in France. From 2006 to 2012, databases allow linking the 
stays over time of a given patient with an anonymous number. In this study, PMSI 
databases were used to identify patient, aged more than 15, with diagnosis of AML 
or MDS and who were alive during the year 2012. Then, patients who underwent 
hospital stays for chemotherapy during more than 5 days were identified and con-
sidered as neutropenic according to experts opinions. Results: Since 2006, 51,386 
patients with at least one diagnosis of AML or MDS and aged more than 15 were 
identified, from which only, 16,006 had at least one hospital stay in 2012 and 3,468 
were hospitalized more than 5 days for chemotherapy. Among those patients, 55.2% 
were male, mean age was 60.4 years, 30% died during a hospital stay and 19% (664) 
were bone marrow grafted during the year 2012. These patients had 1.8 stays for 
chemotherapy per year with average chemotherapy duration of 27 days. Two third 
of these patients (34%) were diagnosed in 2012 and 23% in 2011. ConClusions: 
Among the 16,006 patients diagnosed AML or SMD and hospitalized in France in 
2012, 3, 468 (21%) received intensive chemotherapy inducing neutropenia, putting 
them at high risk of invasive fungal infection.
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objeCtives: To estimate the number of patients receiving Allogeneic Stem Cell 
Transplant (ASCT) and presenting with graft versus host disease (GVHD) in 2012 in 
France. Methods: French hospital databases named PMSI record medical informa-
tion about all the hospitalizations performed annually in France. From 2006 to 2012, 
databases allow linking the stays of a given patient over time with an anonymous 
number. In this study, PMSI databases were used to identify patient, aged more 
than 15, with allogeneic stem cell transplant through adequate Diagnosis Related 
Group and who were alive, hospitalized during the year 2012. Patients with diag-
nosis of GVHD or typical diagnoses of GVHD symptoms (sclerodermia, diarrhea, 
mucitis and keratitis) were identified. Results: Since 2006 to 2012, 9,855 patients 
received allogeneic stem cell transplant in France of which 3,469 died during a 
hospitalization over the period, with an annual death rate stable around 20%. In 
2012, 3,842 ASCT patients aged more than 15 were hospitalized at least once, and 
the proportion with GVHD was estimated to 40% (1,574). Acute GVHD diagnosis or 
typical GVHD symptoms occurring less than 100 days after grafting appeared in 
274 patients and chronic GVHD was diagnosed in 1300 patients. Mean age was 47.8, 
61.4% were male and 22% of these patients died during a stay in 2012. Among the 
ASCT patients hospitalized in 2012, only 5% were grafted in 2006 and this figure 
regularly increased with the year of the procedure to reach 35% grafted in 2012, cor-
responding to a mean annual mortality rate of around 20%. ConClusions: Among 
the 3,842 ASCT patients hospitalized in France in 2012, 1,574 (40%) presented GVHD, 
putting them at higher risk of immunosuppression and invasive fungal infection, 
but also at higher risk of death.
PSY18
the PreSence oF AnxietY AMong eleMentArY SchoolS oBeSe children
Germán Z.1, Botár A.2, Sziládiné Fusz K.1, Pakai A.3, Boncz I.4, Fullér N.1, Oláh A.1
1University of Pécs, Pécs, Hungary, 2Balassa János Hospital, Szekszárd, Hungary, 3University of 
Pécs, Zalaegerszeg, Hungary, 4Faculty of Health Sciences, University of Pécs, Pécs, Hungary
objeCtives: From among the consequences of the obesity very considerable the 
emotional and distressful disturbances with which it grew fat children day, than 
day they fight. Assessing a what kind of measure the sport influences it on was our 
aim the nutritional and the mood life, furthermore, that the obesity influences the 
learning and the mood life. Methods: We made a questionnaire survey in the 
primary schools of Szekszárd, 13-14 year ones among students. Inclusion it was a 
criterion that only 7-8. are class children may have taken a part in the examination, 
furthermore without parents consent, and sufferers may not have taken a part in 
the examination only in a serious illness. All element 149 heads. At the compila-
tion of the questionnaire used Helena (Healthy Lifestile in Europe by Nutritrion in 
Adolescence) name from a project for us essential questions, and we complemented 
it their edited our questionnaire implied altogether 150 questions with questions, 
6 years, would be 34% lower. ConClusions: Treatment with nilotinib is expected 
to result in better health outcomes, with more patients achieving TFR. This initial 
TKI investment should reflect itself in long term economic benefits.
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objeCtives: Familial Amyloid Polyneuropathy (FAP) is a rare, rapidly progressive, 
debilitating and life-threatening neurodegenerative disease. Pre-symptomatic 
genetic testing (PST) can contribute to reduce FAP prevalence, informing carriers 
about risk of transmission to offspring’s and available reproductive options such as 
Pre Natal Diagnosis (PND) or Pre Implantation Genetic Diagnosis (PGD). This study 
aims to describe FAP carrier’s reproductive options after PST and to analyse its 
socio-demographic determinants. Methods: Data from a cohort of 145 FAP carriers 
that underwent PST at Medical Genetics Unit (HP/CHUC – Portugal, 2000-2012) was 
used to analyse reproductive options of FAP carrier’s. An econometric logistic model 
was specified to identify determinants for natural reproduction option. Results: 
The subjects were mainly women (55%) with mean age of 35 years (SD= 15) at PST 
entry. Most participants were in a relationship 92/145 (63%) and mean number years 
of education was 9 years (SD= 14). 75/145 (52%) of subjects were already parents, 
reporting a total of 144 children. 21/145 (14%) subjects decided not to have offspring 
following their positive test result. No child adoption was reported. 27/145 (19%) 
of subjects report offspring posteriori to PST: 19/27 (70%) subjects undergo natural 
reproduction and 8/27 (30%) reproduction with PND or PGD support. A total of 9 off-
spring non-FAP carriers (with PND/PGD) and 24 offspring from natural reproduction 
were observed until data collection. The logistic regression for decide on natural 
reproduction confirms statistical significance (p-value< 0.05) for only two variables: 
being in relationship and having previous children. No statistical significance was 
observed for gender, age at PST or number of education years. ConClusions: 
There is evidence of a high proportion of carriers with offspring’s when initiate 
PST and high proportion of natural reproduction within FAP carriers after PST. An 
ethical physiological case-by-case approach is essential to learn more about the 
determinants for preventing FAP offspring transmission.
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objeCtives: To describe the prevalence of outpatient prescription opiate use 
among patients with Commercial, Medicare Supplemental, or Medicaid insurance 
in the US after 2010. Methods: Patients were identified using the Truven Health 
Commercial and Medicare Supplemental databases from 2010-2013 and Medicaid 
Multi-State databases from 2010-2012. We estimated the proportion of patients with 
at least one outpatient opiate prescription for each calendar year among patients 
with continuous medical and pharmacy enrollment for the entire calendar year, 
stratified by insurance type and age (< 18, 18-64, 65+). Average opiate days supply 
per calendar year was also described. Results: On average, a total of 32.9 million 
(m) patients were included in each calendar year analysis with an average of 6.7m 
Commercially-insured children, 20.2m Commercially-insured non-elderly adults, 
2.5m Medicare Supplemental adults (age 65+), 2.6m Medicaid-insured children and 
0.8m Medicaid-insured adults per year. Among commercially-insured non-elderly 
adults, the prevalence of opiate prescriptions decreased from 25.1% to 23.4% from 
2010 to 2013 (p< 0.001) with a similar decrease among Medicare Supplemental 
patients (29.5% to 27.6%, p< 0.001). Among Medicaid adults, opiate prescription 
prevalence was lower prevalence in 2012 (38.9%) than in 2010 (44.1%) or 2011 (45.2%). 
Among children (age < 18), opiate prescription prevalence use was slightly higher for 
Medicaid than commercially-insured children (9.9% versus 7.4%, p< 0.001); opiate 
prescription prevalence dropped by 15.3% among commercially-insured patients 
from 2010 to 2013 (p< 0.001) and by 12.1% among Medicaid children from 2010 to 2012 
(p< 0.001). Average annual days supply increased over time among Medicaid adults 
(92.8 to 100.5 days), commercially-insured non-elderly adults (41.7 to 44.5 days) and 
Medicare Supplemental adults (65.9 to 68.6 days); days supply per year was steady 
among children (calendar year range: 7.5-9.1). ConClusions: There were modest 
reductions in the prevalence of prescription opiate use from 2010-2013. Further and 
more detailed monitoring is needed to parallel efforts to curtail inappropriate use.
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objeCtives: No national registries for chronic lymphocytic leukaemia (CLL) exist 
in Germany. The objective of this analysis was to examine the number of patients 
with CLL diagnosed (with or without other diagnoses of cancer) and to character-
ize the types of treatment being utilized and care settings using sickness funds 
claim data. Methods: This analysis evaluates data from 1,771,225 beneficiaries 
in 2012 from different statutory sickness funds. Patients with CLL were identified 
by ICD-10 C91.1*, oncological co-diagnoses by ICD-10 C00-79; D37-48 and chemo-
therapy by Anatomical Therapeutic Chemical (ATC) Code L01*, pharmacy number 
(PZN) 9999092 and/or operating and procedure code (OPS) 854*. Results: In total, 
1,405 patients with a diagnosis C91.1* (CLL) were identified (prevalence 79/100,000) 
with 60.2% were male and 39.8% female. Overall, 32.2% of patients with CLL had a 
co-diagnosis with another cancer; 25.1% melanoma (C43-44), 21.3% had neoplasms 
with unknown behaviour (D37-48), 11.8% had malignant male GU neoplasms (90% 
